Cytodyn Inc (CYDY)

[DonDonDonDon]

It is my guess that more leronlimab patients passed away than placebo patients in the severe group. We have literally been given zero topline data from the severe group. I'm pretty sure they'd be touting the severe results if they were even a little bit positive. So the opposite can be deduced.

What if leronlimab's trial had more overall deaths in the leronlimab arm in both critical and severe combined? If there were more treatment deaths than placebo in the severe arm, then it is likely that the whole trial had more deaths in the leronlimab arm since the severe arm of the trial was 5/6ths of the trial and the critials only had a 24% mortality benefit.